Format

Send to

Choose Destination
J Am Acad Dermatol. 2015 Aug;73(2):255-7. doi: 10.1016/j.jaad.2015.05.015. Epub 2015 Jun 6.

Experience with Holter monitoring during propranolol therapy for infantile hemangiomas.

Author information

1
Nationwide Children's Hospital, Columbus, Ohio; University of Mississippi Medical Center, Jackson, Mississippi.
2
Nationwide Children's Hospital, Columbus, Ohio.
3
Nationwide Children's Hospital, Columbus, Ohio. Electronic address: Esteban.fernandezfaith@nationwidechildrens.org.

Abstract

BACKGROUND:

Although adverse events in children treated with propranolol have proven rare, the appropriate methods of assessing cardiovascular risk and monitoring for toxicity when the medication is used for infantile hemangiomas remain unclear.

OBJECTIVE:

We sought to analyze Holter monitor reports of otherwise healthy patients on propranolol for infantile hemangiomas to determine the incidence of sustained arrhythmias and to evaluate the utility of Holter monitoring in the outpatient setting.

METHODS:

We retrospectively reviewed the charts of patients with infantile hemangioma who underwent 24-hour Holter monitoring after initiation or dose escalation of propranolol between 2011 and 2014.

RESULTS:

In all, 43 patients aged 1.8 to 36.2 months, with 44 Holter monitor reports, were included in the study. No sustained arrhythmias were revealed. The treatment plan was not altered in any patient based on the Holter monitor report.

LIMITATIONS:

This was a retrospective study design.

CONCLUSION:

Our study suggests that Holter monitoring may be unnecessary in otherwise healthy patients with infantile hemangioma older than 12 weeks who are treated with propranolol in the outpatient setting.

KEYWORDS:

infantile hemangiomas; medication safety; pediatric dermatology; propranolol; systemic therapies; vascular lesions

PMID:
26054433
DOI:
10.1016/j.jaad.2015.05.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center